Pulmonary hypertension in rheumatoid arthritis — Relation with the duration of the disease

Udayakumar, N; Venkatesan, S.; Rajendiran, C

doi:10.1016/j.ijcard.2007.04.084

Cited by 34 publications

(19 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with traditional risk factors for cardiopulmonary disease were excluded from the study, and only three (6.7%) patients with rheumatoid arthritis had coexisting clinically significant fibrotic lung disease. This meant 20% of the rheumatoid arthritis patients included in this study had isolated pulmonary hypertension by echocardiography [81]. A similar study evaluating 40 Turkish patients with rheumatoid arthritis found that 11 (27.5%) had pulmonary artery systolic pressure ⩾30 mmHg on echocardiography; presence of joint deformity was the only significant difference between those with pulmonary hypertension and those without [82].…”

Section: Vascular Diseasementioning

confidence: 83%

“…However, isolated pulmonary hypertension has also been described [80][81][82][83]. UDAYAKUMAR et al [81] compared 45 patients with rheumatoid arthritis to 45 healthy age-matched controls, and found a significantly higher rate of asymptomatic pulmonary hypertension (defined as pulmonary artery systolic pressure ⩾30 mmHg by Doppler echocardiography) among those with rheumatoid arthritis (26.7% versus 4.5%). This was especially true for older patients and those with longer disease duration.…”

Section: Vascular Diseasementioning

confidence: 99%

See 1 more Smart Citation

Rheumatoid arthritis-associated lung disease

et al. 2015

View full text Add to dashboard Cite

Section: Vascular Diseasementioning

confidence: 83%

Section: Vascular Diseasementioning

confidence: 99%

Rheumatoid arthritis-associated lung disease

et al. 2015

View full text Add to dashboard Cite

“…Pulmonary arterial hypertension (PAH) affects 0.5–15% of patients with connective tissue diseases (CTDs) and is one of the leading causes of death in systemic sclerosis (SSc) and mixed connective tissue disease (MCTD) (). Despite increasing recognition of PAH in CTDs, the diagnosis is often delayed, which may lead to unfavorable outcomes in these patients ().…”

mentioning

confidence: 99%

Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension

Khanna

Gladue

Channick

et al. 2013

Arthritis & Rheumatism

190

141

View full text Add to dashboard Cite

Objectives Pulmonary arterial hypertension (PAH) affects up to 15% of patients with connective tissue diseases (CTD). Previous recommendations developed as part of larger efforts in PAH did not provide detailed recommendations for patients with CTD-PAH. Therefore, we sought to develop recommendations for screening and early detection of CTD-PAH. Methods We performed a systematic review for the screening and diagnosis of PAH in CTD by searching the literature. Using the RAND/UCLA methodology, we developed case scenarios followed by 2 stages of voting—first international experts from a variety of specialties voted anonymously on the appropriateness of each case scenario and then the experts met in a face-to-face meeting to discuss and resolve discrepant votes to arrive at consensus recommendations. Results The key recommendations state that patients with systemic sclerosis (SSc) should be screened for PAH. In addition, mixed connective tissue diseases (MCTD) or other CTD’s with scleroderma features should also be screened for PAH (scleroderma-spectrum disorder). Initial screening evaluation in patients with SSc and scleroderma-spectrum disorders include pulmonary function test (PFT) including diffusion capacity carbon monoxide (DLCO), transthoracic echocardiogram (TTE), and NT- Pro BNP. In SSc and spectrum disorders, TTE and PFT should be performed on annual basis. The full screening panel (TTE, PFT, and NT-ProBNP) should be performed as soon as any new signs or symptoms are present. Conclusion We provide consensus-based, evidence-driven recommendations for screening and early detection of CTD-PAH. It is our hope that these recommendations will lead to earlier detection of CTD-PAH and ultimately improve patient outcomes.

show abstract

“…Die Entwicklung einer klinisch relevanten pulmonalarteriel len Hypertonie ist bei Patienten mit rheu matoider Arthritis mit der Erkrankungs dauer assoziiert, sie tritt aber insgesamt sel tener als bei anderen systemischen Binde gewebserkrankungen wie der Sklerodermie oder dem Lupus erythematodes auf. [21]. …”

Section: Vaskulitis Und Pulmonalarterielle Hypertonieunclassified

Lungenbeteiligung bei rheumatoider Arthritis

Niedermeyer

2008

Pneumologe

View full text Add to dashboard Cite

Die rheumatoide Arthritis ist eine fortschreitende entzündliche Auto immunerkrankung des Bindegewe bes. Die Prävalenz beträgt ca. 1% in der erwachsenen Bevölkerung. Frau en sind 2 bis 3mal häufiger betrof fen als Männer. Die Hauptmanifes tation ist eine symmetrische ero sive Synoviitis mit dem Befall großer und kleiner Gelenke. Der systemische Charakter der Erkrankung wird durch das Auftreten subkutaner Knötchen, einer Vaskulitis, einer Perikarditis oder einer Episkleritis im Rahmen der Erkrankung deutlich. Pulmonale und pleurale Erkrankungen treten bei Pa tienten mit chronischer Polyarthritis häufiger auf, nicht selten bleiben die se Manifestationen jedoch asympto matisch.

show abstract

Pulmonary hypertension in rheumatoid arthritis — Relation with the duration of the disease

Cited by 34 publications

References 6 publications

Rheumatoid arthritis-associated lung disease

Rheumatoid arthritis-associated lung disease

Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial Hypertension

Lungenbeteiligung bei rheumatoider Arthritis

Contact Info

Product

Resources

About